280 assets in Pancreatic Ductal Adenocarcinoma

Therapeutic assets addressing Pancreatic Ductal Adenocarcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Daraxonrasib Pancreatic Ductal Adenocarcinoma	Revolution Medicines, Inc.	P3	BB (66)
Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, Dimer Pancreatic Ductal Adenocarcinoma	OHSU Knight Cancer Institute	P2	BB (66)
Rmc-6236 Pancreatic Ductal Adenocarcinoma	Tango Therapeutics, Inc.	P3	BB (66)
S-1 Pancreatic Ductal Adenocarcinoma	Genentech, Inc.	P2	BB (65)
Ivospemin Pancreatic Ductal Adenocarcinoma	Panbela Therapeutics, Inc.	P2/3	BB (64)
Oxaliplatin Pancreatic Ductal Adenocarcinoma	Jonsson Comprehensive Cancer Center	P4	BB (64)
(R)-(1-(4-Fluorophenyl)-6-((1-Methyl-1H-Pyrazol-4-Yl)Sulfonyl)-1,4,5,6,7,8-Hexahydro-4Ah-Pyrazolo(3,4-G)Isoquinolin-4A-Yl)(4-(Trifluoromethyl)Pyridin-2-Yl)Methanone Pancreatic Ductal Adenocarcinoma	Corcept Therapeutics	P3	BB (64)
Fludarabine Pancreatic Ductal Adenocarcinoma	Beijing Biotech	P2	B (63)
Fluorouracilum Pancreatic Ductal Adenocarcinoma	Jonsson Comprehensive Cancer Center	P3	B (63)
Selinexor Pancreatic Ductal Adenocarcinoma	University Health Network, Toronto	P2	B (63)
Atezolizumab Pancreatic Ductal Adenocarcinoma	Genentech, Inc.	P2	B (62)
Capecitabine Pancreatic Ductal Adenocarcinoma	Shenyang Sunshine Pharmaceutical Co., LTD.	P3	B (62)
Serplulimab Pancreatic Ductal Adenocarcinoma	West China Hospital	P3	B (62)
Tislelizumab Pancreatic Ductal Adenocarcinoma	Daniel Breadner	P2	B (62)
Cyclophosphamide Pancreatic Ductal Adenocarcinoma	City of Hope Medical Center	P2	B (61)
Durvalumab Pancreatic Ductal Adenocarcinoma	Jonsson Comprehensive Cancer Center	P2	B (61)
Selumetinib Pancreatic Ductal Adenocarcinoma	National Cancer Institute (NCI)	P2	B (61)
Etoposide Pancreatic Ductal Adenocarcinoma	University Health Network, Toronto	P2	B (60)
Irinotecan Pancreatic Ductal Adenocarcinoma	Jonsson Comprehensive Cancer Center	P3	B (60)
Irinotecan Sucrosofate Pancreatic Ductal Adenocarcinoma	NRG Oncology	P3	B (60)
Polo-Like Kinase 1 Inhibitor Nms-1286937 Pancreatic Ductal Adenocarcinoma	OHSU Knight Cancer Institute	P2	B (60)
Cis-Diamminedichloroplatinum Ii Pancreatic Ductal Adenocarcinoma	Jonsson Comprehensive Cancer Center	P2/3	B (59)
Nivolumab Pancreatic Ductal Adenocarcinoma	Georgetown University	P2	B (59)
Carboplatin Pancreatic Ductal Adenocarcinoma	Akeso	P2	B (58)
Cobimetinib Pancreatic Ductal Adenocarcinoma	University Health Network, Toronto	P2	B (58)
Lenvatinib Pancreatic Ductal Adenocarcinoma	Fudan University	P2	B (58)
Mitazalimab Pancreatic Ductal Adenocarcinoma	University of Pennsylvania	P2	B (58)
Surufatinib Pancreatic Ductal Adenocarcinoma	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	P2	B (58)
Atebimetinib Pancreatic Ductal Adenocarcinoma	Immuneering Corporation	P3	B (57)
Botensilimab Pancreatic Ductal Adenocarcinoma	Benjamin Spieler	P2	B (57)
Jab 3312 Pancreatic Ductal Adenocarcinoma	Allist Pharmaceuticals, Inc.	P1/2	B (57)
Mgnp Pancreatic Ductal Adenocarcinoma	Immuneering Corporation	P3	B (57)
Quemliclustat Pancreatic Ductal Adenocarcinoma	Arcus Biosciences, Inc.	P3	B (57)
Sulfur Hexafluoride Pancreatic Ductal Adenocarcinoma	Adenocyte, LLC	P2	B (57)
Zoldonrasib Pancreatic Ductal Adenocarcinoma	Revolution Medicines, Inc.	P3	B (57)
(±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone Pancreatic Ductal Adenocarcinoma	Brian Anderson, MD	P4	B (56)
Levofolinic Acid Pancreatic Ductal Adenocarcinoma	Shenzhen Xinhe Biomedical	P2	B (56)
Adriamycin Pancreatic Ductal Adenocarcinoma	ImmunityBio, Inc.	P2	CCC (55)
Cetuximab Pancreatic Ductal Adenocarcinoma	Verastem, Inc.	P2	CCC (55)
Olaparib Pancreatic Ductal Adenocarcinoma	OHSU Knight Cancer Institute	P2	CCC (55)
Ponsegromab Pancreatic Ductal Adenocarcinoma	Pfizer	P2/3	CCC (55)
Pembrolizumab Pancreatic Ductal Adenocarcinoma	GV20 Therapeutics	P2	CCC (54)
Samuraciclib Pancreatic Ductal Adenocarcinoma	University Health Network, Toronto	P1/2	CCC (54)
Agen1423 Pancreatic Ductal Adenocarcinoma	Bruno Bockorny	P2	CCC (53)
Autogene Cevumeran Pancreatic Ductal Adenocarcinoma	Genentech, Inc.	P2	CCC (53)
Balstilimab Pancreatic Ductal Adenocarcinoma	Benjamin Spieler	P2	CCC (53)
Brigatinib Pancreatic Ductal Adenocarcinoma	University Health Network, Toronto	P2	CCC (53)
Ceritinib Pancreatic Ductal Adenocarcinoma	University Health Network, Toronto	P2	CCC (53)
Ciprofloxacin Pancreatic Ductal Adenocarcinoma	GERCOR - Multidisciplinary Oncology Cooperative Group	P2	CCC (53)
Colchicinum Pancreatic Ductal Adenocarcinoma	University Health Network, Toronto	P2	CCC (53)

Showing 1 to 50 of 280 assets

PreviousPage 1 of 6Next